An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

NCT01074333 · clinicaltrials.gov ↗

TERMINATED

Status

146

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated due to low recruitment

Conditions

Colorectal Neoplasm

Interventions

DRUG: Cetuximab

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]